2024-09-30 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that develops and commercializes medicines for a range of diseases, including HIV/AIDS, hepatitis B and C, cancer, and inflammatory diseases.

**Performance Analysis:**

1. **Performance vs. S&P 500 (VOO):** 
    - GILD's cumulative return is -12.61%, while VOO's is 133.28%.
    - This reflects a significant underperformance of GILD compared to the S&P 500.
    - The relative divergence of -145.89 indicates that GILD is currently 6.16% of the way from the minimum to maximum historical divergence.
2. **Recent Price Action:**
    - Closing Price: $84.25
    - 5-day Moving Average: $83.41
    - 20-day Moving Average: $81.92
    - 60-day Moving Average: $76.62
    - The price is currently above all moving averages, suggesting a potential upward trend.
3. **Technical Indicators:**
    - RSI: 72.76 - Indicates the stock is currently in the overbought territory.
    - PPO: -0.21 - Shows a weakening momentum, potentially signaling a slowdown in upward price movement.
    - Delta_Previous_Relative_Divergence: -0.37 - Suggests a short-term downward trend in relative divergence.
    - Expected_Return: 0.0% - The expected return over the next 5 years is currently 0%.
4. **Recent Earnings and Outlook:**

| Date       | EPS    | Revenue         |
|------------|--------|-----------------|
| 2024-08-08 | 1.29   | 6.95 B$        |
| 2024-05-08 | -3.34  | 6.69 B$        |
| 2023-11-07 | 1.75   | 7.05 B$        |
| 2023-08-04 | 0.84   | 6.60 B$        |
| 2024-08-08 | 0.84   | 6.60 B$        |

- The most recent earnings report (2024-08-08) showed an EPS of 1.29, which exceeded analysts' expectations by 0.18. 
- Revenue for the quarter was $6.95 billion, slightly exceeding analysts' estimates.
- Gilead Sciences' core HIV business is expected to continue performing well, but the company faces significant competition in other areas such as Hepatitis C and oncology.
-  The company has launched new products in recent years and continues to invest in research and development, which is expected to drive future growth. 

5. **News and Recent Issues:**

- **FINBOLD**:  "Gilead Sciences shares have been under pressure in recent months due to concerns about the company's growth prospects. However, some analysts believe that the stock is undervalued and has the potential to rebound. Gilead Sciences is also facing competition from other pharmaceutical companies in its core markets. The company is investing heavily in research and development to develop new drugs, which could help it to maintain its market share in the long term."
- **Analyst Opinions:** There is a mixed outlook among analysts, with some seeing potential for growth based on ongoing research and development efforts and others expressing concerns about competition in existing markets. 
- **Performance Highlights:** Recent positive performance, including exceeding earnings expectations in the latest quarter, could indicate a potential upward trend, but long-term growth prospects remain under scrutiny.

**Summary and Conclusion:**

Gilead Sciences Inc. (GILD) is a large pharmaceutical company facing a mixed outlook. While it has a strong position in HIV treatment and has seen recent positive earnings, the company's overall growth potential is uncertain, with strong competition in key markets.  GILD has a history of underperforming the broader market, reflected by its significant negative divergence from the S&P 500. Current technical indicators suggest a possible upward trend, with recent price action moving above key moving averages. However, high RSI indicates overbought territory, and the PPO suggests weakening momentum. The long-term outlook depends on Gilead's ability to navigate competition, succeed in its research and development efforts, and introduce new successful products. Investors should monitor Gilead Sciences' future earnings reports and developments to assess the company's long-term growth potential and make informed decisions. 
